Zacks Investment Research on MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies
Sarepta Therapeutics SRPT announced plans to submit supplementary new drug applications (sNDAs) to the FDA for its two ...
In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led to hospitalization and a diagnosis of ...
Zacks Investment Research on MSN
KROS stock: What to know about Rinvatercept in DMD
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results